<DOC>
	<DOCNO>NCT02532868</DOCNO>
	<brief_summary>The purpose study assess safety tolerability MK-0457 ( VX-680 ) , Aurora kinase inhibitor , participant advance solid tumor . Bioavailability oral formulation also assess . The primary study hypothesis administration MK-0457 sufficiently safe tolerate permit study .</brief_summary>
	<brief_title>A VX-680 ( Aurora Kinase Inhibitor ) Study Patients With Advanced Cancer ( 0457-002 )</brief_title>
	<detailed_description />
	<criteria>Patients least 18 year age recurrent nonresponsive solid tumor , cancer standard therapy exist . Patients treatment investigational therapy within past 30 day . Patients certain type blood cancer leukemia lymphoma . Patients uncontrolled congestive heart failure ( CHF ) , chest pain , heart attack within past 3 month , undergone bone marrow stem cell transplantation . Patient pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>